225 related articles for article (PubMed ID: 12887682)
1. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
Mishizen-Eberz AJ; Guttmann RP; Giasson BI; Day GA; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
J Neurochem; 2003 Aug; 86(4):836-47. PubMed ID: 12887682
[TBL] [Abstract][Full Text] [Related]
2. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.
Mishizen-Eberz AJ; Norris EH; Giasson BI; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
Biochemistry; 2005 May; 44(21):7818-29. PubMed ID: 15909996
[TBL] [Abstract][Full Text] [Related]
3. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
4. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
[TBL] [Abstract][Full Text] [Related]
5. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
Conway KA; Harper JD; Lansbury PT
Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
[TBL] [Abstract][Full Text] [Related]
6. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
7. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
[TBL] [Abstract][Full Text] [Related]
8. Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations.
Lewis KA; Yaeger A; DeMartino GN; Thomas PJ
J Bioenerg Biomembr; 2010 Feb; 42(1):85-95. PubMed ID: 20148295
[TBL] [Abstract][Full Text] [Related]
9. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease.
El-Agnaf OM; Jakes R; Curran MD; Wallace A
FEBS Lett; 1998 Nov; 440(1-2):67-70. PubMed ID: 9862427
[TBL] [Abstract][Full Text] [Related]
10. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.
Kahle PJ; Neumann M; Ozmen L; Müller V; Odoy S; Okamoto N; Jacobsen H; Iwatsubo T; Trojanowski JQ; Takahashi H; Wakabayashi K; Bogdanovic N; Riederer P; Kretzschmar HA; Haass C
Am J Pathol; 2001 Dec; 159(6):2215-25. PubMed ID: 11733371
[TBL] [Abstract][Full Text] [Related]
11. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
[TBL] [Abstract][Full Text] [Related]
12. Neuropathology of synuclein aggregates.
Duda JE; Lee VM; Trojanowski JQ
J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
[TBL] [Abstract][Full Text] [Related]
13. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
Li W; Lee MK
J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.
Albani D; Peverelli E; Rametta R; Batelli S; Veschini L; Negro A; Forloni G
FASEB J; 2004 Nov; 18(14):1713-5. PubMed ID: 15345691
[TBL] [Abstract][Full Text] [Related]
15. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
16. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.
Kahle PJ; Neumann M; Ozmen L; Haass C
Ann N Y Acad Sci; 2000; 920():33-41. PubMed ID: 11193173
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
Li W; Lesuisse C; Xu Y; Troncoso JC; Price DL; Lee MK
J Neurosci; 2004 Aug; 24(33):7400-9. PubMed ID: 15317865
[TBL] [Abstract][Full Text] [Related]
18. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
Conway KA; Harper JD; Lansbury PT
Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
[TBL] [Abstract][Full Text] [Related]
19. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
Li W; West N; Colla E; Pletnikova O; Troncoso JC; Marsh L; Dawson TM; Jäkälä P; Hartmann T; Price DL; Lee MK
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2162-7. PubMed ID: 15684072
[TBL] [Abstract][Full Text] [Related]
20. Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease.
Fares MB; Maco B; Oueslati A; Rockenstein E; Ninkina N; Buchman VL; Masliah E; Lashuel HA
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E912-21. PubMed ID: 26839406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
